141200-24-0
141200-24-0 结构式
基本信息
2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-
5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
物理化学性质
DMF:20.0(Max Conc. mg/mL);47.56(Max Conc. mM)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-120160 | 达格列酮 Darglitazone | 141200-24-0 | 1 mg | 350元 |
| 2025/05/22 | HY-120160 | 达格列酮 Darglitazone | 141200-24-0 | 5 mg | 780元 |
| 2025/05/22 | HY-120160 | 达格列酮 Darglitazone | 141200-24-0 | 10 mg | 1250元 |
常见问题列表
|
PPAR-γ
|
In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ.
Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult.
| Animal Model: | Male diabetic ob/ob mice |
| Dosage: | 1 mg/kg |
| Administration: | Oral administration; daily; for 7 days |
| Result: | Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. |